Format

Send to

Choose Destination
Leuk Res. 2015 Feb;39(2):138-43. doi: 10.1016/j.leukres.2014.11.011. Epub 2014 Nov 29.

Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.

Author information

1
Department of Hematology and Stem Cell Transplant Unit, IRCCS "Casa Sollievo della Sofferenza" Hospital, 71013 San Giovanni Rotondo, Italy. Electronic address: giovannirossi.fr@gmail.com.
2
Department of Hematology and Stem Cell Transplant Unit, IRCCS "Casa Sollievo della Sofferenza" Hospital, 71013 San Giovanni Rotondo, Italy.
3
Department of Hygiene, Catholic University of Sacred Heart, 00165 Rome, Italy.
4
Department of Hematology, "Vito Fazzi" Hospital, 73100 Lecce, Italy.
5
Department of Hematology, "Perrino" Hospital, 72100 Brindisi, Italy.
6
Department of Hematology, "Riuniti" Hospital, 71100 Foggia, Italy.
7
Department of Hematology, "San Giuseppe Moscati" Hospital, 74121 Taranto, Italy.

Abstract

Minimal residual disease (MRD) of 30 adult AML patients was monitored by multiparameter flow cytometry (MFC) and WT1 expression before and after allogeneic stem cell transplantation (allo-SCT). Diagnostic performance of pre-transplant MRD measured by MFC was higher than that obtained by WT1 expression. Comparable results were displayed at day +30 post-transplant, while better values by WT1 compared to MFC were found at day +90. Positive MRD by MFC predicted a shorter disease free survival (DFS) before and 1 month after transplant (p=0.006 and p=0.005), while only high WT1 levels at 1 month from the transplant significantly impacted on DFS (p=0.010). Our results support the idea that MRD monitoring by MFC should be suggested before and 30 days after the transplant, while WT1 expression should be preferred after this procedure. The assessment of MRD at day +30 from allo-SCT is recommended as post transplant check-point for the predictive role displayed, independently of the method used.

KEYWORDS:

Acute myeloid leukemia; Allogeneic stem cell transplantation; Minimal residual disease; Multiparameter flow cytometry; WT1 expression

PMID:
25498507
DOI:
10.1016/j.leukres.2014.11.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center